Underwriting Agreement



 Exhibit 10.2 
 4,500,000 Shares 
 MASTEC, INC. 
 Common Stock, Par Value $0.10 Per Share 
 UNDERWRITING AGREEMENT 
 June 1, 2009 







 June 1, 2009 
 MORGAN STANLEY & CO. INCORPORATED 
 As Representative of
the Underwriters 
 c/o Morgan Stanley & Co. Incorporated 
 1585 Broadway 
 New York, New York 10036 
 Ladies and
Gentlemen: 
 The several Selling Stockholders named in Schedule I hereto (the “Selling Stockholders”) propose to sell to the
several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 4,500,000 shares of Common Stock, par value $0.10 per share (the “Firm Shares”) of MasTec, Inc., a Florida corporation (the
“Company”). The Selling Stockholders also propose to sell to the several Underwriters not more than an aggregate of additional 675,000 shares of Common Stock, par value $0.10 per share (the “Additional Shares”) of
the Company if and to the extent that you shall have determined to exercise the right to purchase such shares of common stock granted to the Underwriters in Section 2 hereof. The Firm Shares and the Additional Shares are hereinafter
collectively referred to as the “Shares.” The shares of Common Stock, par value $0.10 per share, of the Company outstanding are hereinafter referred to as the “Common Stock.” Morgan Stanley & Co.
Incorporated has agreed to act as Representative of the Underwriters (the “Representative”) in connection with the offering and sale of the Shares. 
 The Company has filed with the Securities and Exchange Commission (the “Commission”) a shelf registration statement, including a prospectus, (the file number of which is 333-158502) on Form S-3,
relating to securities (the “Shelf Securities”) including the Shares, to be issued from time to time by the Company. The registration statement, at any given time, including the amendments thereto to such time, the exhibits and any
schedules thereto at such time, the documents incorporated by reference therein pursuant to Item 12 of Form S-3 under the Securities Act of 1933, as amended (the “Securities Act”), at such time and the documents otherwise
deemed to be a part thereof or included therein by regulations promulgated under the Securities Act, as amended to the date of this Agreement, is hereinafter referred to as the “Registration Statement”; and the related prospectus
covering the Shelf Securities dated April 8, 2009 in the form first used to confirm sales of the Shares (or in the form first made available to the Underwriters by the Company to meet requests of purchasers pursuant to Rule 173 under the
Securities Act) is hereinafter referred to as the “Basic Prospectus.” The Basic Prospectus, as supplemented by the prospectus supplement specifically relating to the Shares in the form first used to confirm sales of Shares (or in
the form first made available to the Underwriters by the Company to meet requests of purchasers pursuant to Rule 173 under the Securities Act) is hereinafter referred to as the “Prospectus,” and the term “preliminary
prospectus” means any preliminary form of the Prospectus. For purposes of this Agreement, “free writing prospectus” has the meaning set forth in Rule 405 under the Securities Act, “Time of Sale Prospectus”
means the preliminary prospectus together with the free writing 







 prospectuses, if any, each identified in Schedule II hereto, and “broadly available road show” means a
“bona fide electronic road show” as defined in Rule 433(h)(5) under the Securities Act that has been made available without restriction to any person. As used herein, the terms “Registration Statement,” “Basic
Prospectus,” “preliminary prospectus,” “Time of Sale Prospectus” and “Prospectus” shall include the documents, if any, incorporated by reference therein. The terms “supplement,”
“amendment,” and “amend” as used herein with respect to the Registration Statement, the Basic Prospectus, the Time of Sale Prospectus, any preliminary prospectus or any free writing prospectus shall include all
documents subsequently filed by the Company with the Commission pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are incorporated by reference therein. For purposes of this Agreement, all
references to the Registration Statement, any preliminary prospectus, the Prospectus or any amendment or supplement to any of the foregoing shall be deemed to include the copy filed with the Commission pursuant to its Electronic Data Gathering,
Analysis and Retrieval system (EDGAR) and/or Interactive Data Electronic Applications (IDEA) system or any successor system or database. 
  

	 	1.	Representations and Warranties 

 (A) The Company, as
of the date hereof and as of the First Closing Date (as defined in Section 4), and as of the Option Closing Date (as defined in Section 2), if any, represents and warrants to and agrees with each of the Underwriters that: 
 (a) The Registration Statement has become effective; no stop order suspending the effectiveness of the Registration Statement is in effect, and no
proceedings for such purpose are pending before or threatened by the Commission. 
 (b) As of the date the Registration Statement was filed,
the Company was a well-known seasoned issuer (as defined in Rule 405 of the Securities Act) eligible to use the Registration Statement as an automatic shelf registration statement and the Company has not received notice that the Commission objects
to the use of the Registration Statement as an automatic shelf registration statement. 
 (c) (i) The Registration Statement, when it became
effective, did not contain and, as amended or supplemented, if applicable, will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not
misleading, (ii) the Registration Statement as of the date hereof does not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not
misleading, (iii) the Registration Statement and the Prospectus comply and, as amended or supplemented, if applicable, will comply in all material respects with the Securities Act and the applicable rules and regulations of the Commission
thereunder, (iv) the Time of Sale Prospectus does not, and at the time of each sale of the Shares in connection with the offering when the Prospectus is not yet available to prospective purchasers and at the Closing Date (as defined in
Section 4), the Time of Sale Prospectus, as then amended or supplemented by the Company, if applicable, will not, contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the
light of the circumstances under which they were made, not misleading, (v) each 

  

 2 








 
broadly available road show, if any, when considered together with the Time of Sale Prospectus, does not contain any untrue statement of a material fact or
omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading and (vi) the Prospectus does not contain and, as amended or supplemented, if applicable, will
not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, except that the representations and
warranties set forth in this paragraph do not apply to statements or omissions in the Registration Statement, the Time of Sale Prospectus or the Prospectus based upon information relating to any Underwriter furnished to the Company in writing by
such Underwriter through you expressly for use therein. 
 (d) The documents incorporated or deemed to be incorporated by reference in the
Time of Sale Prospectus or the Prospectus, at the time they were or hereafter are filed with the Commission, complied and will comply in all material respects with the requirements of the Exchange Act and the rules and regulations of the Commission
thereunder (the “Exchange Act Regulations”), and, when read together with the other information in the Time of Sale Prospectus or the Prospectus at its date and at the Closing Date, did not and will not contain an untrue statement
of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. 
 (e) The Company is not an “ineligible issuer” in connection with the offering pursuant to Rules 164, 405 and 433 under the Securities Act. Any free writing prospectus that the Company is required to file pursuant to Rule 433(d)
under the Securities Act has been, or will be, filed with the Commission in accordance with the requirements of the Securities Act and the applicable rules and regulations of the Commission thereunder. Each free writing prospectus that the Company
has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act or that was prepared by or behalf of or used or referred to by the Company complies or will comply in all material respects with the requirements of the Securities
Act and the applicable rules and regulations of the Commission thereunder. Except for the free writing prospectuses, if any, identified in Schedule II hereto, and electronic road shows, if any, furnished to you before first use, the Company has not
prepared, used or referred to, and will not, without your prior consent, prepare, use or refer to, any free writing prospectus. Any issuer free writing prospectus as defined in Rule 433(h) under the Securities Act, as of its issue date and at all
subsequent times through the completion of the public offer and sale of Shares or until any earlier date that the Company notified or notifies the Representative as required in Section 6(e) and 6(f), did not, does not and will not include any
information that conflicted, conflicts or will conflict with the information contained in the Registration Statement, the Time of Sale Prospectus or the Prospectus, including any document incorporated by reference therein and any preliminary or
other prospectus deemed to be a part thereof that has not been superseded or modified. 
 (f) The Company has been duly incorporated, is
validly existing as a corporation in good standing under the laws of the jurisdiction of its incorporation, has the corporate power and authority to own its property and to conduct its business as described in the Time of Sale Prospectus and is duly
qualified to transact business and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in
good standing would not have a material adverse effect on the Company and its subsidiaries, taken as a whole. 
  

 3 








 (g) Each “significant subsidiary” as such term is defined in Item 1-02 of Regulation S-X
promulgated by the Commission (each a “Significant Subsidiary”) of the Company is listed on Schedule III hereto. Each Significant Subsidiary of the Company has been duly incorporated or organized, is validly existing as a
corporation or limited liability company in good standing under the laws of the respective jurisdiction of incorporation or organization, has the corporate or limited liability power and authority to own its respective property and to conduct its
respective businesses as described in the Time of Sale Prospectus and is duly qualified to transact business and is in good standing in each jurisdiction in which the conduct of its respective businesses or ownership or leasing of property requires
such qualification, except to the extent that the failure to be so qualified or be in good standing would not have a material adverse effect on the Company and its subsidiaries, taken as a whole; all of the issued shares of capital stock of each
subsidiary of the Company have been duly and validly authorized and issued, are fully paid and non-assessable and are owned directly or indirectly by the Company, free and clear of all liens, encumbrances, equities or claims, except as set forth in
the Registration Statement. 
 (h) This Agreement has been duly authorized, executed and delivered by the Company. 
 (i) The authorized capital stock of the Company conforms as to legal matters to the description thereof contained in each of the Time of Sale Prospectus
and the Prospectus. 
 (j) The shares of Common Stock outstanding have been duly authorized and are validly issued, fully paid and
non-assessable. 
 (k) The Shares have been duly authorized and are validly issued, fully paid and non-assessable. 
 (l) The execution and delivery by the Company of, and the performance by the Company of its obligations under, this Agreement will not contravene any
provision of applicable law or the certificate of incorporation or by-laws of the Company or any agreement or other instrument binding upon the Company or any of its subsidiaries that is material to the Company and its subsidiaries, taken as a
whole, or any judgment, order or decree of any governmental body, agency or court having jurisdiction over the Company or any subsidiary, and no consent, approval, authorization or order of, or qualification with, any governmental body or agency is
required for the performance by the Company of its obligations under this Agreement, except such as may be required by the securities or Blue Sky laws of the various states in connection with the offer and sale of the Shares. 
 (m) There has not occurred any material adverse change, or any development involving a prospective material adverse change, in the condition, financial
or otherwise, or in the earnings, business or operations of the Company and its subsidiaries, taken as a whole, from that set forth in the Time of Sale Prospectus. 
 (n) There are no legal or governmental proceedings pending or threatened to which the Company or any of its subsidiaries is a party or to which any of the properties of the Company or any of its subsidiaries is
subject other than proceedings accurately described 

  

 4 








 
in all material respects in the Time of Sale Prospectus and proceedings that would not have a material adverse effect on the Company and its subsidiaries,
taken as a whole, or on the power or ability of the Company to perform its obligations under this Agreement or to consummate the transactions contemplated by the Time of Sale Prospectus. 
 (o) Each preliminary prospectus filed as part of the registration statement as originally filed or as part of any amendment thereto, or filed pursuant to
Rule 424 under the Securities Act, complied when so filed in all material respects with the Securities Act and the applicable rules and regulations of the Commission thereunder. 
 (p) The Company is not required to register as an “investment company” as such term is defined in the Investment Company Act of 1940, as
amended. 
 (q) Except as disclosed in the Registration Statement, the Company and its subsidiaries (i) are in compliance with any and
all applicable foreign, federal, state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (“Environmental
Laws”), (ii) have received all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses and (iii) are in compliance with all terms and conditions of any such
permit, license or approval, except where such noncompliance with Environmental Laws, failure to receive required permits, licenses or other approvals or failure to comply with the terms and conditions of such permits, licenses or approvals would
not, singly or in the aggregate, have a material adverse effect on the Company and its subsidiaries, taken as a whole. 
 (r) Except as
disclosed in the Registration Statement, there are no costs or liabilities associated with Environmental Laws (including, without limitation, any capital or operating expenditures required for clean-up, closure of properties or compliance with
Environmental Laws or any permit, license or approval, any related constraints on operating activities and any potential liabilities to third parties) which would, singly or in the aggregate, have a material adverse effect on the Company and its
subsidiaries, taken as a whole. 
 (s) Except as disclosed in the Registration Statement, there are no contracts, agreements or
understandings between the Company and any person granting such person the right to require the Company to file a registration statement under the Securities Act with respect to any securities of the Company or to require the Company to include such
securities with the Shares registered pursuant to the Registration Statement. 
 (t) The pro forma consolidated financial statements of the
Company and its subsidiaries and the related notes thereto included in the Preliminary Prospectus, the Prospectus and the Registration Statement or incorporated by reference in the Preliminary Prospectus, the Prospectus and the Registration
Statement, present fairly the information contained therein, have been prepared in accordance with the Commission’s rules and guidelines with respect to pro forma financial statements and have been properly presented on the basis described
therein, and the assumptions used in the preparation thereof are reasonable and the adjustments used therein are appropriate to give effect to the transactions and circumstances referred to therein. 
  

 5 








 (u) Neither the Company nor any of its subsidiaries or affiliates, nor any director, officer, or
employee, nor, to the Company’s knowledge, any agent or representative of the Company or of any of its subsidiaries or affiliates, has taken or will take any action in furtherance of an offer, payment, promise to pay, or authorization or
approval of the payment or giving of money, property, gifts or anything else of value, directly or indirectly, to any “government official” (including any officer or employee of a government or government-owned or controlled entity or of a
public international organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for political office) to influence official action or secure an improper
advantage; and the Company and its subsidiaries and affiliates have conducted their businesses in compliance with applicable anti-corruption laws and have instituted and maintain and will continue to maintain policies and procedures designed to
promote and achieve compliance with such laws and with the representation and warranty contained herein. 
 (v) The operations of the Company
and its subsidiaries are and have been conducted at all times in material compliance with all applicable financial recordkeeping and reporting requirements, including those of the Bank Secrecy Act, as amended by Title III of the Uniting and
Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT Act), and the applicable anti-money laundering statutes of jurisdictions where the Company and its subsidiaries conduct
business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the “Anti-Money Laundering Laws”), and no action,
suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the best knowledge of the
Company, threatened. 
 (w) (i) The Company represents that neither the Company nor any of its subsidiaries (collectively, the
“Entity”) or any director, officer, employee, agent, affiliate or representative of the Entity, is an individual or entity (“Person”) that is, or is owned or controlled by a Person that is: 
 (A) the subject of any sanctions administered or enforced by the U.S. Department of Treasury’s Office of Foreign Assets Control
(“OFAC”), the United Nations Security Council (“UNSC”) or other sanctions authority (collectively, “Sanctions”), nor 
 (B) located, organized or resident in a country or territory that is the subject of Sanctions (including, without limitation,
Burma/Myanmar, Cuba, Iran, North Korea, Sudan and Syria). 
 (ii) The Company represents and covenants that for the past 5 years, the Entity
has not knowingly engaged in, is not now knowingly engaged in, and will not engage in, any dealings or transactions with any Person, or in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions.

  

 6 








 (x) Subsequent to the respective dates as of which information is given in each of the Registration
Statement, the Time of Sale Prospectus and the Prospectus, (i) the Company and its subsidiaries have not incurred any material liability or obligation, direct or contingent, nor entered into any material transaction; (ii) the Company has
not purchased any of its outstanding capital stock, nor declared, paid or otherwise made any dividend or distribution of any kind on its capital stock other than ordinary and customary dividends; and (iii) there has not been any material change
in the capital stock, short-term debt or long-term debt of the Company and its subsidiaries except in each case as described in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus, respectively. 
 (y) The Company and its subsidiaries have good and marketable title in fee simple to all real property and good and marketable title to all personal
property owned by them which is material to the business of the Company and its subsidiaries, in each case free and clear of all liens, encumbrances and defects except such as are described in the Time of Sale Prospectus or such as do not materially
affect the value of such property and do not interfere with the use made and proposed to be made of such property by the Company and its subsidiaries; and any real property and buildings held under lease by the Company and its subsidiaries are held
by them under valid, subsisting and enforceable leases with such exceptions as are not material and do not interfere with the use made and proposed to be made of such property and buildings by the Company and its subsidiaries, in each case except as
described in the Time of Sale Prospectus. 
 (z) The Company and its subsidiaries own or possess, or can acquire on reasonable terms, all
material patents, patent rights, licenses, inventions, copyrights, know-how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures), trademarks, service marks and trade names
currently employed by them in connection with the business now operated by them, and neither the Company nor any of its subsidiaries has received any notice of infringement of or conflict with asserted rights of others with respect to any of the
foregoing which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would have a material adverse effect on the Company and its subsidiaries, taken as a whole. 
 (aa) No material labor dispute with the employees of the Company or any of its subsidiaries exists, except as described in the Time of Sale Prospectus,
or, to the knowledge of the Company, is imminent; and the Company is not aware of any existing, threatened or imminent labor disturbance by the employees of any of its principal suppliers, manufacturers or contractors that could have a material
adverse effect on the Company and its subsidiaries, taken as a whole. 
 (bb) The Company and each of its subsidiaries are insured by
insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which they are engaged; neither the Company nor any of its subsidiaries has been refused any
insurance coverage sought or applied for, and neither the Company nor any of its subsidiaries has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage
from similar insurers as may be necessary to continue its business at a cost that would not have a material adverse effect on the Company and its subsidiaries, taken as a whole, except as described in the Time of Sale Prospectus. 
  

 7 








 (cc) The Company and its subsidiaries possess all certificates, authorizations and permits issued by the
appropriate federal, state or foreign regulatory authorities necessary to conduct their respective businesses, and neither the Company nor any of its subsidiaries has received any notice of proceedings relating to the revocation or modification of
any such certificate, authorization or permit which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would have a material adverse effect on the Company and its subsidiaries, taken as a whole, except as
described in the Time of Sale Prospectus. 
 (dd) The Company and each of its subsidiaries maintain a system of internal accounting controls
sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial
statements in conformity with generally accepted accounting principles and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the
recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. Except as described in the Time of Sale Prospectus, since the end of the Company’s
most recent audited fiscal year, there has been (i) no material weakness in the Company’s internal control over financial reporting (whether or not remediated) and (ii) no change in the Company’s internal control over financial
reporting that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting. 
 (ee) Except as described in the Time of Sale Prospectus, the Company has not sold, issued or distributed any shares of Common Stock during the six-month period preceding the date hereof, including any sales pursuant to Rule 144A under,
or Regulation D or S of, the Securities Act, other than shares issued pursuant to employee benefit plans, qualified stock option plans or other employee compensation plans or pursuant to outstanding options, rights or warrants. 
 (B) Each of the Selling Stockholders, severally, as of the date hereof and as of the First Closing Date (as defined in Section 4), and as of the
Option Closing Date (as defined in Section 2), if any, represents and warrants to and agrees with each of the Underwriters that: 
 (a)
All consents, approvals, authorizations and orders necessary for the execution and delivery by such Selling Stockholder of this Agreement and for the sale and delivery of the Shares to be sold by such Selling Stockholder hereunder, have been
obtained; and such Selling Stockholder has full right, power and authority to enter into this Agreement and to sell, assign, transfer and deliver the Shares to be sold by such Selling Stockholder hereunder. 
 (b) The sale of the Shares to be sold by such Selling Stockholder hereunder and the compliance by such Selling Stockholder with all of the provisions of
this Agreement and the consummation of the transactions herein contemplated will not conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, any statute, indenture, mortgage, deed of
trust, loan agreement or other agreement or instrument to which such Selling Stockholder is a party or by which such Selling Stockholder is bound or to which any of the property or assets of such Selling Stockholder is subject, nor will such action
result in any violation 
  

 8 








 of the provisions of any Organizational Documents (as defined below) of such Selling Stockholder or any statute or any
order, rule or regulation of any court or governmental agency or body having jurisdiction over such Selling Stockholder or the property of such Selling Stockholder; “Organizational Documents” means the trust agreement and all other
governing documents which grant or limit the power of a trust or the power of a trustee of a trust; 
 (c) Such Selling Stockholder has, and
immediately prior to the First Closing Date and, if applicable, Option Closing Date (as defined in Section 2) such Selling Stockholder will have, good and valid title to the Shares to be sold by such Selling Stockholder hereunder, free and
clear of all liens, encumbrances, equities or claims; and, upon delivery of such Shares and payment therefor pursuant hereto, good and valid title to such Shares, free and clear of all liens, encumbrances, equities or claims, will pass to the
several Underwriters. 
 (d) During the period beginning from the date hereof and continuing to and including the date 90 days after the date
of the Prospectus, not to offer, sell contract to sell or otherwise dispose of, except as provided hereunder, any securities of the Company that are substantially similar to the Shares, including but not limited to any securities that are
convertible into or exchangeable for, or that represent the right to receive, Stock or any such substantially similar securities (other than (i) pursuant to employee stock option plans existing on, or upon the conversion or exchange of
convertible or exchangeable securities outstanding as of, the date of this Agreement, or (ii) pursuant to the call, redemption or repurchase by the Company of its 8% Subordinated Convertible Notes due 2013), without your prior written consent.
Notwithstanding the foregoing, if (i) during the last 17 days of the 90-day restricted period the Company issues an earnings release or material news or a material event relating to the Company occurs, or (ii) prior to the expiration of
the 90-day restricted period, the Company announces that it will release earnings results during the 16-day period beginning on the last day of the 90-day period, the restrictions imposed in this clause shall continue to apply until the expiration
of the 18-day period beginning on the date of the issuance of the earnings release or the occurrence of the material news or material event. 
 (e) Such Selling Stockholder has not taken and will not take, directly or indirectly, any action which is designed to or which has constituted or which might reasonably be expected to cause or result in stabilization or manipulation of the
price of any security of the Company to facilitate the sale or resale of the Shares. 
 (f) To the extent that any statements or omissions
made in the Time of Sale Prospectus, the Prospectus and the Registration Statement or any amendment or supplement thereto are made in reliance upon and in conformity with written information furnished to the Company by such Selling Stockholder
expressly for use therein, such Time of Sale Prospectus and the Registration Statement did, and the Prospectus and any further amendments or supplements to the Registration Statement and the Prospectus, when they become effective or are filed with
the Commission, as the case may be, will conform in all material respects to the requirements of the Securities Act and the rules and regulations of the Commission thereunder and will not contain any untrue statement of a material fact or omit to
state any material fact required to be stated therein or necessary to make the statements therein not misleading. 
  

 9 








 (g) In order to document the Underwriters’ compliance with the reporting and withholding provisions
of the Tax Equity and Fiscal Responsibility Act of 1982 with respect to the transactions herein contemplated, such Selling Stockholder will deliver to you prior to or at the Closing Date a properly completed and executed United States Treasury
Department Form W 9 (or other applicable form or statement specified by Treasury Department regulations in lieu thereof). 
 (h) Such Selling
Stockholder is not prompted to sell Shares by any information concerning the Company which is not set forth in the Time of Sale Prospectus. 
 2. Agreements to Sell and Purchase. Each Selling Stockholder hereby agrees, severally and not jointly, to sell the respective number of Firm Shares set forth in Schedule I hereto opposite its name to the several Underwriters, and
each Underwriter, upon the basis of the representations and warranties herein contained, but subject to the conditions hereinafter stated, agrees, severally and not jointly, to purchase from the Selling Stockholders the respective number of Firm
Shares set forth in Schedule I hereto opposite such Underwriter’s name at $11.76 a share (the “Purchase Price”). 
 On
the basis of the representations and warranties contained in this Agreement, and subject to its terms and conditions, each Selling Stockholder agrees, severally and not jointly, to sell up to the respective number of Additional Shares set forth in
Schedule I hereto opposite its name to the Underwriters, and the Underwriters shall have the right to purchase, severally and not jointly, up to an aggregate of 675,000 Additional Shares at the Purchase Price. You may exercise this right on behalf
of the Underwriters in whole or from time to time in part by giving written notice not later than 30 days after the date of this Agreement. Any exercise notice shall specify the number of Additional Shares to be purchased by the Underwriters and the
date on which such shares are to be purchased. Each purchase date must be at least one business day after the written notice is given and may not be earlier than the First Closing Date nor later than ten business days after the date of such notice.
On each day, if any, that Additional Shares are to be purchased (an “Option Closing Date”), which may be the First Closing Date (the First Closing Date and each Option Closing Date, if any, being sometimes referred to as a
“Closing Date”), each Underwriter agrees, severally and not jointly, to purchase the number of Additional Shares (subject to such adjustments to eliminate fractional shares as you may determine) that bears the same proportion to the
total number of Additional Shares to be purchased on such Option Closing Date as the number of Firm Shares set forth in Schedule I hereto opposite the name of such Underwriter bears to the total number of Firm Shares. 
 3. Terms of Public Offering. The Selling Stockholders and the Company are advised by you that the Underwriters propose to make a public offering
of their respective portions of the Shares as soon after the Registration Statement and this Agreement have become effective as in your judgment is advisable. The price of the Shares initially offered to the public is referred to herein as the
“Public Offering Price”. 
 4. Payment and Delivery. Payment for the Firm Shares shall be made to each Selling
Stockholder in Federal or other funds immediately available in New York City against delivery of such Firm Shares for the respective accounts of the several Underwriters at 10:00 a.m., New York City time, on June 5, 2009, or at such other time
on the same or such other date, not later than June 12, 2009, as shall be designated in writing by you. The time and date of such payment and delivery are herein referred to as the “First Closing Date.” 
  

 10 








 Payment for any Additional Shares shall be made to each Selling Stockholder in Federal or other funds
immediately available in New York City against delivery of such Additional Shares for the respective accounts of the several Underwriters at 10:00 a.m., New York City time, on the date specified in the corresponding notice described in
Section 2 or at such other time on the same or on such other date, in any event not later than July 3, 2009, as shall be designated in writing by you. 
 The Firm Shares and Additional Shares shall be registered in such names and in such denominations as you shall request in writing not later than one full business day prior to the First Closing Date or the applicable
Option Closing Date, as the case may be. The Firm Shares and Additional Shares shall be delivered to you on the First Closing Date or an Option Closing Date, as the case may be, for the respective accounts of the several Underwriters, with any
transfer taxes payable in connection with the transfer of the Shares to the Underwriters duly paid, against payment of the Purchase Price therefor. 
 5. Conditions to the Underwriters’ Obligations 
 The several obligations of the Underwriters to purchase and pay for the Firm
Shares on the First Closing Date and for the Additional Shares on each Option Closing Date are subject to the following conditions: 
 (a)
Subsequent to the execution and delivery of this Agreement and prior to the Closing Date, there shall not have occurred any change, or any development involving a prospective change, in the condition, financial or otherwise, or in the earnings,
business or operations of the Company and its subsidiaries, taken as a whole, from that set forth in the Time of Sale Prospectus as of the date of this Agreement that, in your judgment, is material and adverse and that makes it, in your judgment,
impracticable to market the Shares on the terms and in the manner contemplated in the Time of Sale Prospectus. 
 (b) The Representative
shall have received on the Closing Date a certificate (addressed to each Underwriter), dated the Closing Date and signed by an executive officer of the Company, to the effect that the representations and warranties of the Company contained in this
Agreement are true and correct as of the Closing Date and that the Company has complied with all of the agreements and satisfied all of the conditions on its part to be performed or satisfied hereunder on or before the Closing Date. 
 The officer signing and delivering such certificate may rely upon the best of his or her knowledge as to proceedings threatened. 
 (c) The Representative shall have received on the Closing Date an opinion (addressed to each Underwriter) of (i) Greenberg Traurig, P.A., outside
counsel for the Company and MasTec North America, Inc., and (ii) outside counsel satisfactory to the Representative to each Significant Subsidiary other than MasTec North America, Inc. with respect to each such Significant Subsidiary, dated the
Closing Date, to the effect that: 
 (i) the Company has been duly incorporated, is validly existing as a corporation in good
standing under the laws of the jurisdiction of its incorporation, has the corporate power and authority to own its property and to conduct its business as described in the Time of Sale Prospectus; 
  

 11 








 (ii) each Significant Subsidiary of the Company has been duly incorporated, is validly
existing as a corporation in good standing under the laws of the jurisdiction of its incorporation, has the corporate power and authority to own its property and to conduct its business as described in the Time of Sale Prospectus; 
 (iii) the authorized capital stock of the Company conforms as to legal matters to the description thereof contained in each of the Time
of Sale Prospectus and the Prospectus; 
 (iv) [reserved]; 
 (v) each Significant Subsidiary’s authorized capital stock or limited liability company interests is as set forth on Exhibit A, and
based solely on our review of such Significant Subsidiary’s stock ledger, the Company is the direct or indirect owner of record of the shares of such Significant Subsidiary’s capital stock or limited liability company interests as set
forth on Exhibit A; 
 (vi) the Shares have been duly authorized and are validly issued, fully paid and non-assessable;

 (vii) this Agreement has been duly authorized, executed and delivered by the Company; 
 (viii) the execution and delivery by the Company of, and the performance by the Company of its obligations under, this Agreement will not
contravene any provision of applicable law or the certificate of incorporation or by-laws of the Company or, to the best of such counsel’s knowledge, any agreement that has been filed as an exhibit to the Registration Statement, or, to the best
of such counsel’s knowledge, any judgment, order or decree of any governmental body, agency or court having jurisdiction over the Company or any Significant Subsidiary, and no consent, approval, authorization or order of, or qualification with,
any governmental body or agency is required for the performance by the Company of its obligations under this Agreement, except such as may be required by the securities or Blue Sky laws of the various states in connection with the offer and sale of
the Shares; 
 (ix) the statements relating to legal matters or documents included in (A) the Registration Statement
under the captions “Description of Common and Preferred Stock,” “Plan of Distribution” and (B) the Time of Sale Prospectus and the Prospectus under the caption “Underwriting”, in each case fairly summarize in all
material respects such matters or documents; 
 (x) after due inquiry, such counsel does not know of any legal or
governmental proceedings pending or threatened to which the Company or any Significant Subsidiary is a party or to which any of the properties of the Company or any Significant Subsidiary is subject that are required to be described in the
Registration Statement or the Prospectus and are not so described by Item 103 of Regulation S-K under the Securities Act; 
  

 12 








 (xi) the Company is not required to register as an “investment company” as such
term is defined in the Investment Company Act of 1940, as amended; and 
 (xii) (A) in the opinion of such counsel, the
Registration Statement and the Prospectus (except for the financial statements and financial schedules and other financial and statistical data included therein, as to which such counsel need not express any opinion) appear on their face to be
appropriately responsive in all material respects to the requirements of the Securities Act and the applicable rules and regulations of the Commission thereunder, and (B) nothing has come to the attention of such counsel that causes such
counsel to believe that (1) the Registration Statement or the prospectus included therein (except for the financial statements and financial schedules and other financial and statistical data included therein, as to which such counsel need not
express any belief) at the time the Registration Statement became effective contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary to make the statements therein not
misleading, (2) the Time of Sale Prospectus (except for the financial statements and financial schedules and other financial and statistical data included therein, as to which such counsel need not express any belief) as of the date of this
Agreement and as amended or supplemented, if applicable, as of the Closing Date contained or contains any untrue statement of a material fact or omitted or omits to state a material fact necessary in order to make the statements therein, in the
light of the circumstances under which they were made, not misleading or (3) the Prospectus (except for the financial statements and financial schedules and other financial and statistical data included therein, as to which such counsel need
not express any belief) as of its date and as amended or supplemented, if applicable, as of the Closing Date contained or contains any untrue statement of a material fact or omitted or omits to state a material fact necessary in order to make the
statements therein, in the light of the circumstances under which they were made, not misleading. 
 (d) The Representative shall have
received on the Closing Date an opinion (addressed to each Underwriter) of Shearman & Sterling LLP, counsel for the Underwriters, dated the Closing Date, in form and substance satisfactory to the Representative. 
 With respect to Section 5(c)(xii) above, Greenberg Traurig, P.A. and Shearman & Sterling LLP may state that their opinions and beliefs are
based upon their participation in the preparation of the Registration Statement, the Time of Sale Prospectus and Prospectus and any amendments or supplements thereto and review and discussion of the contents thereof, but are without independent
check or verification, except as specified. 
 The opinion of Greenberg Traurig, P.A. described in Section 5(c) above shall be rendered
to the Underwriters at the request of the Company and shall so state therein. 
 (e) The Representative shall have received, on each of the
date hereof and the Closing Date, a letter (addressed to each Underwriter) dated the date hereof or the Closing Date, as the case may be, in form and substance satisfactory to the Representative, from BDO Seidman, independent public accountants for
the Company and Pumpco, Inc., containing statements and information of 

  

 13 








 
the type ordinarily included in accountants’ “comfort letters” to underwriters with respect to the financial statements and certain financial
information (including pro forma financial information) contained in the Registration Statement, the Time of Sale Prospectus and the Prospectus; provided that the letter delivered on the Closing Date shall use a “cut-off date” not
earlier than the date hereof. 
 (f) The Representative shall have received, on each of the date hereof and the Closing Date, a letter
(addressed to each Underwriter) dated the date hereof or the Closing Date, as the case may be, in form and substance satisfactory to the Representative, from Eide Bailly LLP, independent public accountants for Wanzek Construction, Inc., a North
Dakota corporation, containing statements and information of the type ordinarily included in accountants’ “comfort letters” to underwriters with respect to the financial statements and certain financial information contained in the
Registration Statement, the Time of Sale Prospectus and the Prospectus; provided that the letter delivered on the Closing Date shall use a “cut-off date” not earlier than the date hereof. 
 (g) The “lock-up” agreements, each substantially in the form of Exhibit A hereto, between you and certain shareholders, officers and directors
of the Company relating to sales and certain other dispositions of shares of Common Stock or certain other securities, delivered to you on or before the date hereof, shall be in full force and effect on the Closing Date. 
 (h) The Representative shall have received on the Closing Date an opinion (addressed to each Underwriter) of Albert de Cardenas, Esq., inside counsel for
the Company, dated the Closing Date, to the effect that (i) the shares of Common Stock outstanding have been duly authorized and are validly issued, fully paid and non-assessable, (ii) the Company is duly qualified to transact business and
is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not have a
material adverse effect on the Company and its subsidiaries, taken as a whole, (iii) each Significant Subsidiary is duly qualified to transact business and is in good standing in each jurisdiction in which the conduct of its business or its
ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not have a material adverse effect on the Company and its subsidiaries, taken as a whole and
(iv) except as otherwise disclosed in the Registration Statement, there are no material pending legal proceedings to which the Company or any of its subsidiaries is a party or of which any of their property is the subject. 
 (i) At the Closing Date, the Shares shall have been approved for listing on the New York Stock Exchange, subject only to official notice of issuance.

 (j) The Representative shall have received on the Closing Date a certificate (addressed to each Underwriter), dated the Closing Date and
signed by an authorized representative of each of the Selling Stockholders, to the effect that the representations and warranties of such Selling Stockholder contained in this Agreement are true and correct as of the Closing Date and that such
Selling Stockholder has complied with all of the agreements and satisfied all of the conditions on its part to be performed or satisfied hereunder on or before the Closing Date. 
  

 14 








 (k) The Representative shall have received on the Closing Date an opinion (addressed to each Underwriter)
of Fabyanske, Westra, Hart & Thomson P.A., counsel for the Selling Stockholders, dated the Closing Date, to the effect that: 
 (i) This Agreement has been duly executed and delivered by or on behalf of each Selling Stockholder; and the sale of the Shares to be sold by each Selling Stockholder hereunder and the compliance by such Selling
Stockholder with all of the provisions of this Agreement and the consummation of the transactions herein contemplated will not conflict with or result in a breach or violation of any terms or provisions of, or constitute a default under, any
statute, indenture, mortgage, deed of trust, loan agreement or other agreement or instrument known to such counsel to which such Selling Stockholder is a party or by which such Selling Stockholder is bound or to which any of the property or assets
of such Selling Stockholder is subject, nor will such action result in any violation of the provisions of any Organizational Documents of such Selling Stockholder or any order, rule or regulation known to such counsel of any court or governmental
agency or body having jurisdiction over such Selling Stockholder or the property of such Selling Stockholder; 
 (ii) No
consent, approval, authorization or order of any court or governmental agency or body is required for the consummation of the transactions contemplated by this Agreement in connection with the Shares to be sold by each Selling Stockholder hereunder,
which have been duly obtained and are in full force and effect, such as have been obtained under the Act and such as may be required under state securities or Blue Sky laws in connection with the purchase and distribution of such Shares by the
Underwriters; 
 (iii) Immediately prior to the First Closing Date or, if applicable, Option Closing Date, each Selling
Stockholder had good and valid title to the Shares to be sold at such First Closing Date or, if applicable, Option Closing Date by such Selling Stockholder under this Agreement, free and clear of all liens, encumbrances, equities or claims, and full
right, power and authority to sell, assign, transfer and deliver the Shares to be sold by such Selling Stockholder hereunder; and 
 (iv) Good and valid title to such Shares, free and clear of all liens, encumbrances, equities or claims, has been transferred to each of the several Underwriters who have purchased such Shares in good faith and without notice of any such
lien, encumbrance, equity or claim or any other adverse claim within the meaning of the Uniform Commercial Code. 
 In rendering the opinion
in paragraph (iii), such counsel may rely upon a certificate of each Selling Stockholder in respect of matters of fact as to ownership of, and liens, encumbrances, equities or claims on, the Shares sold by such Selling Stockholder, provided that
such counsel shall state that they believe that both you and they are justified in relying upon such certificate. 
 The several obligations
of the Underwriters to purchase Additional Shares hereunder are subject to the delivery to you on the applicable Option Closing Date of such documents as you may reasonably request with respect to the good standing of the Company, the due
authorization and issuance of the Additional Shares to be sold on such Option Closing Date and other matters related to the delivery of such Additional Shares. 
  

 15 








 6. Covenants of the Company. The Company covenants with each Underwriter as follows: 
 (a) To furnish to you, without charge, three signed copies of the Registration Statement (including exhibits thereto) and for delivery to each other
Underwriter a conformed copy of the Registration Statement (without exhibits thereto) and to furnish to you in New York City, without charge, prior to 10:00 a.m. New York City time on the business day next succeeding the date of this Agreement and
during the period mentioned in Section 6(e) or 6(f) below, as many copies of the Time of Sale Prospectus, the Prospectus and any supplements and amendments thereto or to the Registration Statement as you may reasonably request. 
 (b) Before amending or supplementing the Registration Statement, the Time of Sale Prospectus or the Prospectus, to furnish to you a copy of each such
proposed amendment or supplement and not to file any such proposed amendment or supplement to which you reasonably object, and to file with the Commission within the applicable period specified in Rule 424(b) under the Securities Act any prospectus
required to be filed pursuant to such Rule. 
 (c) To furnish to you a copy of each proposed free writing prospectus to be prepared by or on
behalf of, used by, or referred to by the Company and not to use or refer to any proposed free writing prospectus to which you reasonably object. 
 (d) Not to take any action that would result in an Underwriter or the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of the Underwriter
that the Underwriter otherwise would not have been required to file thereunder. 
 (e) If the Time of Sale Prospectus is being used to
solicit offers to buy the Shares at a time when the Prospectus is not yet available to prospective purchasers and any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Time of Sale Prospectus in
order to make the statements therein, in the light of the circumstances, not misleading, or if any event shall occur or condition exist as a result of which the Time of Sale Prospectus conflicts with the information contained in the Registration
Statement then on file, or if, in the opinion of counsel for the Underwriters, it is necessary to amend or supplement the Time of Sale Prospectus to comply with applicable law, forthwith to prepare, file with the Commission and furnish, at its own
expense, to the Underwriters and to any dealer upon request, either amendments or supplements to the Time of Sale Prospectus so that the statements in the Time of Sale Prospectus as so amended or supplemented will not, in the light of the
circumstances when delivered to a prospective purchaser, be misleading or so that the Time of Sale Prospectus, as amended or supplemented, will no longer conflict with the Registration Statement, or so that the Time of Sale Prospectus, as amended or
supplemented, will comply with applicable law. 
  

 16 








 (f) If, during such period after the first date of the public offering of the Shares as in the opinion of
counsel for the Underwriters the Prospectus (or in lieu thereof the notice referred to in Rule 173(a) under the Securities Act) is required by law to be delivered in connection with sales by an Underwriter or dealer, any event shall occur or
condition exist as a result of which it is necessary to amend or supplement the Prospectus in order to make the statements therein, in the light of the circumstances when the Prospectus (or in lieu thereof the notice referred to in Rule 173(a) under
the Securities Act) is delivered to a purchaser, not misleading, or if, in the opinion of counsel for the Underwriters, it is necessary to amend or supplement the Prospectus to comply with applicable law, forthwith to prepare, file with the
Commission and furnish, at its own expense, to the Underwriters and to the dealers (whose names and addresses you will furnish to the Company) to which Shares may have been sold by you on behalf of the Underwriters and to any other dealers upon
request, either amendments or supplements to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not, in the light of the circumstances when the Prospectus (or in lieu thereof the notice referred to in Rule
173(a) under the Securities Act) is delivered to a purchaser, be misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law. 
 (g) To endeavor to qualify the Shares for offer and sale under the securities or Blue Sky laws of such jurisdictions as you shall reasonably request. 
 (h) To make generally available to the Company’s security holders and to you as soon as practicable an earning statement covering a period of at
least twelve months beginning with the first fiscal quarter of the Company occurring after the date of this Agreement which shall satisfy the provisions of Section 11(a) of the Securities Act and the rules and regulations of the Commission
thereunder. 
 (i) The Company will use its best efforts to affect the listing of the Shares on the New York Stock Exchange before the First
Closing Date. 
 (j) Whether or not the transactions contemplated in this Agreement are consummated or this Agreement is terminated, the
Company agrees to pay or cause to be paid all expenses incident to the performance of its obligations under this Agreement, including: (i) the fees, disbursements and expenses of the Company’s counsel and the Company’s accountants in
connection with the registration and delivery of the Shares under the Securities Act and all other fees or expenses in connection with the preparation and filing of the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus,
the Prospectus, any free writing prospectus prepared by or on behalf of, used by, or referred to by the Company and amendments and supplements to any of the foregoing, including all printing costs associated therewith, and the mailing and delivering
of copies thereof to the Underwriters and dealers, in the quantities hereinabove specified, (ii) the cost of printing or producing any Blue Sky or Legal Investment memorandum in connection with the offer and sale of the Shares under state
securities laws and all expenses in connection with the qualification of the Shares for offer and sale under state securities laws as provided in Section 6(g) hereof, including filing fees and the reasonable fees and disbursements of counsel
for the Underwriters in connection with such qualification and in connection with the Blue Sky or Legal Investment memorandum, (iii) all filing fees and the reasonable fees and disbursements of counsel to the Underwriters incurred in connection
with the review and qualification of the offering of the Shares by the National Association of Securities Dealers, Inc., (iv) all costs and 
  

 17 








 expenses incident to listing the Shares on The New York Stock Exchange, (v) the cost of printing certificates
representing the Shares, (vii) the costs and charges of any transfer agent, registrar or depositary, (vi) the costs and expenses of the Company relating to investor presentations on any “road show” undertaken in connection with
the marketing of the offering of the Shares, including, without limitation, expenses associated with the preparation or dissemination of any electronic roadshow, expenses associated with the production of road show slides and graphics, fees and
expenses of any consultants engaged in connection with the road show presentations with the prior approval of the Company, travel and lodging expenses of the representatives and officers of the Company and any such consultants, and the cost of any
aircraft chartered in connection with the road show, (vii) the document production charges and expenses associated with printing this Agreement and (viii) all other costs and expenses incident to the performance of the obligations of the
Company hereunder for which provision is not otherwise made in this Section; provided, however, that the Selling Shareholders shall be responsible for all underwriting discounts, brokers’ commissions and the like with respect to their
respective Shares and any other fees and expenses incurred by or on their behalf (including, without limitation, fees and expenses of their own counsel and advisors). It is understood, however, that except as provided in this Section, Section 8
entitled “Indemnity and Contribution” and the last paragraph of Section 10 below, the Underwriters will pay all of their costs and expenses, including fees and disbursements of their counsel, stock transfer taxes payable on resale of
any of the Shares by them and any advertising expenses connected with any offers they may make. 
 The Company also covenants with each
Underwriter that, without the prior written consent of the Representative, it will not, during the period ending 90 days after the date of the Prospectus, (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase,
purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable
for Common Stock or (2) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Common Stock, whether any such transaction described in clause (1) or
(2) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise or (3) file any registration statement with the Commission relating to the offering of any shares of Common Stock or any securities
convertible into or exercisable or exchangeable for Common Stock, other than a registration statement on Form S-8 relating to the issuance by the Company of stock options or restricted stock grants pursuant to employee plans in existence on the date
hereof. Notwithstanding the foregoing, if (i) during the last 17 days of the 90-day restricted period the Company issues an earnings release or material news or a material event relating to the Company occurs, or (ii) prior to the
expiration of the 90-day restricted period, the Company announces that it will release earnings results during the 16-day period beginning on the last day of the 90-day period, the restrictions imposed in this paragraph shall continue to apply until
the expiration of the 18-day period beginning on the date of the issuance of the earnings release or the occurrence of the material news or material event. 
 The restrictions contained in the preceding paragraph shall not apply to (a) the Shares to be sold hereunder, (b) the issuance by the Company of shares of Common Stock upon the exercise of an option or
warrant (other than shares of Common Stock issued upon the exercise of stock options granted pursuant to employee plans in existence on the date hereof) or the conversion of a security 

  

 18 








 
outstanding on the date hereof of which the Representative has been advised in writing, (c) the issuance by the Company of stock options or restricted
stock grants pursuant to employee plans in existence on the date hereof, (d) the filing of a registration statement with the Commission relating to the resale of certain shares of Common Stock that may be issued from time to time in connection
with certain “earn-out” provisions related to certain of the Company’s previous acquisitions, (e) the issuance and registration for resale by the Company of up to 2,000,000 shares of Common Stock as consideration for potential
acquisitions, and (f) the issuance by the Company of its 4.00% Senior Convertible Notes due 2014. 
 7. Covenant of the
Underwriters. Each Underwriter severally covenants with each of the Company and each Selling Stockholder not to take any action that would result in the Company or such Selling Stockholder being required to file with the Commission under Rule
433(d) a free writing prospectus prepared by or on behalf of such Underwriter that otherwise would not be required to be filed by the Company or such Selling Stockholder thereunder, but for the action of the Underwriter. 
 8. Indemnity and Contribution. (a) The Company agrees to indemnify and hold harmless each Underwriter, each person, if any, who controls any
Underwriter within the meaning of either Section 15 of the Securities Act or Section 20 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and each affiliate of any Underwriter within the meaning of
Rule 405 under the Securities Act from and against any and all losses, claims, damages and liabilities (including, without limitation, any legal or other expenses reasonably incurred in connection with defending or investigating any such action or
claim) caused by any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or any amendment thereof, any preliminary prospectus, the Time of Sale Prospectus, any issuer free writing prospectus as
defined in Rule 433(h) under the Securities Act, any Company information that the Company has filed, or is required to file, pursuant to Rule 433(d) of the Securities Act, any “road show” (as defined in Rule 433) not constituting an issuer
free writing prospectus as defined in Rule 433(h) under the Securities Act (a “Non-Prospectus Road Show”) or the Prospectus or any amendment or supplement thereto, or caused by any omission or alleged omission to state therein a
material fact required to be stated therein or necessary to make the statements therein not misleading, except insofar as such losses, claims, damages or liabilities are caused by any such untrue statement or omission or alleged untrue statement or
omission based upon information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representative expressly for use therein. 
 (b) Each Selling Stockholder agrees to indemnify and hold harmless each Underwriter, each person, if any, who controls any Underwriter within the meaning of either Section 15 of the Securities Act or
Section 20 of the Exchange Act, and each affiliate of any Underwriter within the meaning of Rule 405 under the Securities Act from and against any and all losses, claims, damages and liabilities (including, without limitation, any legal or
other expenses reasonably incurred in connection with defending or investigating any such action or claim) caused by any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or any amendment
thereof, any preliminary prospectus, the Time of Sale Prospectus, any issuer free writing prospectus as defined in Rule 433(h) under the Securities Act, any Company information that the Company has filed, or is required to file, pursuant to Rule
433(d) of the Securities Act, any Non-Prospectus Road Show or the Prospectus or any amendment or supplement thereto, or 

  

 19 








 
caused by any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not
misleading, insofar as such losses, claims, damages or liabilities are caused by any such untrue statement or omission or alleged untrue statement or omission based upon information furnished to the Company in writing by such Selling Stockholder
expressly for use therein, except insofar as such losses, claims, damages or liabilities are caused by any such untrue statement or omission or alleged untrue statement or omission based upon information relating to any Underwriter furnished to the
Company in writing by such Underwriter through the Representative expressly for use therein; provided, however, that any liabilities that each Selling Shareholder shall have under this Section 8(b) shall not exceed the gross proceeds of
the offering of the Shares received by such Selling Shareholder. 
 (c) Each Underwriter agrees, severally and not jointly, to indemnify and
hold harmless each Selling Stockholder and the Company, its directors, its officers who sign the Registration Statement and each person, if any, who controls such Selling Stockholder and the Company within the meaning of either Section 15 of
the Securities Act or Section 20 of the Exchange Act to the same extent as the foregoing indemnity from such Selling Stockholder and the Company to such Underwriter, but only with reference to information relating to such Underwriter furnished
to the Company in writing by such Underwriter through the Representative expressly for use in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, any issuer free writing prospectus, Non-Prospectus Road Show or the
Prospectus or any amendment or supplement thereto. 
 (d) In case any proceeding (including any governmental investigation) shall be
instituted involving any person in respect of which indemnity may be sought pursuant to Section 8(a), 8(b) or 8(c), such person (the “indemnified party”) shall promptly notify the person against whom such indemnity may be
sought (the “indemnifying party”) in writing and the indemnifying party, upon request of the indemnified party, shall retain counsel reasonably satisfactory to the indemnified party to represent the indemnified party and any others
the indemnifying party may designate in such proceeding and shall pay the fees and disbursements of such counsel related to such proceeding. In any such proceeding, any indemnified party shall have the right to retain its own counsel, but the fees
and expenses of such counsel shall be at the expense of such indemnified party unless (i) the indemnifying party and the indemnified party shall have mutually agreed to the retention of such counsel or (ii) the named parties to any such
proceeding (including any impleaded parties) include both the indemnifying party and the indemnified party and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them. It
is understood that the indemnifying party shall not, in respect of the legal expenses of any indemnified party in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the fees and expenses of more than one
separate firm (in addition to any local counsel) for all such indemnified parties and that all such fees and expenses shall be reimbursed as they are incurred. Such firm shall be designated in writing by the Representative, in the case of parties
indemnified pursuant to Section 8(a) and 8(b), and by the Selling Stockholders and the Company, in the case of parties indemnified pursuant to Section 8(c). The indemnifying party shall not be liable for any settlement of any proceeding
effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party from and against any loss or liability by reason of such
settlement or judgment. Notwithstanding the foregoing sentence, if at any time an indemnified party shall have 

  

 20 








 
requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as contemplated by the second and third sentences of this
paragraph, the indemnifying party agrees that it shall be liable for any settlement of any proceeding effected without its written consent if (i) such settlement is entered into more than 30 days after receipt by such indemnifying party of the
aforesaid request and (ii) such indemnifying party shall not have reimbursed the indemnified party in accordance with such request prior to the date of such settlement. No indemnifying party shall, without the prior written consent of the
indemnified party, effect any settlement of any pending or threatened proceeding in respect of which any indemnified party is or could have been a party and indemnity could have been sought hereunder by such indemnified party, unless such settlement
includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such proceeding. 
 (e) To the extent the indemnification provided for in Section 8(a), 8(b) or 8(c) is unavailable to an indemnified party or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each
indemnifying party under such paragraph, in lieu of indemnifying such indemnified party thereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such losses, claims, damages or liabilities (i) in such
proportion as is appropriate to reflect the relative benefits received by the Selling Stockholders and the Company on the one hand and the Underwriters on the other hand from the offering of the Shares or (ii) if the allocation provided by
clause 8(e)(i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause 8(e)(i) above but also the relative fault of the Selling Stockholders and the Company on
the one hand and of the Underwriters on the other hand in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable considerations. The relative benefits
received by the Selling Stockholders and the Company on the one hand and the Underwriters on the other hand in connection with the offering of the Shares shall be deemed to be in the same respective proportions as the net proceeds from the offering
of the Shares (before deducting expenses) received by the Selling Stockholders and the Company and the total underwriting discounts and commissions received by the Underwriters, in each case as set forth in the table on the cover of the Prospectus,
bear to the aggregate Public Offering Price of the Shares. The relative fault of the Selling Stockholders and the Company on the one hand and the Underwriters on the other hand shall be determined by reference to, among other things, whether the
untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Selling Stockholders and the Company or by the Underwriters and the parties’ relative
intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The Underwriters’ respective obligations to contribute pursuant to this Section 8 are several in proportion to the respective number
of Shares they have purchased hereunder, and not joint. 
 (f) The Selling Stockholders, the Company and the Underwriters agree that it would
not be just or equitable if contribution pursuant to this Section 8 were determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation that does not take
account of the equitable considerations referred to in Section 8(e). The amount paid or payable by an indemnified party as a result of the losses, claims, damages and liabilities referred to in Section 8(e) shall be deemed to include,
subject to the limitations set forth above, any legal or other expenses reasonably incurred by such 

  

 21 








 
indemnified party in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this Section 8, no
Underwriter shall be required to contribute any amount in excess of the amount by which the total price at which the Shares underwritten by it and distributed to the public were offered to the public exceeds the amount of any damages that such
Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act)
shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The remedies provided for in this Section 8 are not exclusive and shall not limit any rights or remedies which may otherwise be available
to any indemnified party at law or in equity. 
 (g) The indemnity and contribution provisions contained in this Section 8 and the
representations, warranties and other statements of the Selling Stockholders and the Company contained in this Agreement shall remain operative and in full force and effect regardless of (i) any termination of this Agreement, (ii) any
investigation made by or on behalf of any Underwriter, any person controlling any Underwriter or any affiliate of any Underwriter or by or on behalf of each Selling Stockholder or the Company, its officers or directors or any person controlling such
Selling Stockholder or the Company and (iii) acceptance of and payment for any of the Shares. 
 9. Termination. The Underwriters
may terminate this Agreement by notice given by you to the Selling Stockholders and the Company, if after the execution and delivery of this Agreement and prior to the Closing Date (i) trading generally shall have been suspended or materially
limited on, or by, as the case may be, any of The New York Stock Exchange, the American Stock Exchange, the Nasdaq National Market, the Chicago Board of Options Exchange, the Chicago Mercantile Exchange or the Chicago Board of Trade,
(ii) trading of any securities of the Company shall have been suspended on any exchange or in any over-the-counter market, (iii) a material disruption in securities settlement, payment or clearance services in the United States shall have
occurred, (iv) any moratorium on commercial banking activities shall have been declared by Federal or New York State authorities or (v) there shall have occurred any outbreak or escalation of hostilities, or any change in financial markets
or any calamity or crisis that, in your judgment, is material and adverse and which, singly or together with any other event specified in this clause (v), makes it, in your judgment, impracticable or inadvisable to proceed with the offer, sale or
delivery of the Shares on the terms and in the manner contemplated in the Time of Sale Prospectus or the Prospectus. 
 10. Effectiveness;
Defaulting Underwriters. This Agreement shall become effective upon the execution and delivery hereof by the parties hereto. 
 If, on
the First Closing Date or an Option Closing Date, as the case may be, any one or more of the Underwriters shall fail or refuse to purchase Shares that it has or they have agreed to purchase hereunder on such date, and the aggregate number of Shares
which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase is not more than one-tenth of the aggregate number of the Shares to be purchased on such date, the other Underwriters shall be obligated severally in the
proportions that the number of Firm Shares set forth opposite their respective names in Schedule I bears to the aggregate number of Firm Shares set forth 

  

 22 








 
opposite the names of all such non-defaulting Underwriters, or in such other proportions as you may specify, to purchase the Shares which such defaulting
Underwriter or Underwriters agreed but failed or refused to purchase on such date; provided that in no event shall the number of Shares that any Underwriter has agreed to purchase pursuant to this Agreement be increased pursuant to this
Section 10 by an amount in excess of one-ninth of such number of Shares without the written consent of such Underwriter. If, on the First Closing Date, any Underwriter or Underwriters shall fail or refuse to purchase Firm Shares and the
aggregate number of Firm Shares with respect to which such default occurs is more than one-tenth of the aggregate number of Firm Shares to be purchased on such date, and arrangements satisfactory to you, each Selling Stockholder and the Company for
the purchase of such Firm Shares are not made within 36 hours after such default, this Agreement shall terminate without liability on the part of any non-defaulting Underwriter, such Selling Stockholder or the Company. In any such case either you,
the Selling Stockholders or the Company shall have the right to postpone the First Closing Date, but in no event for longer than seven days, in order that the required changes, if any, in the Registration Statement, in the Time of Sale Prospectus,
in the Prospectus or in any other documents or arrangements may be effected. If, on an Option Closing Date, any Underwriter or Underwriters shall fail or refuse to purchase Additional Shares and the aggregate number of Additional Shares with respect
to which such default occurs is more than one-tenth of the aggregate number of Additional Shares to be purchased on such Option Closing Date, the non-defaulting Underwriters shall have the option to (i) terminate their obligation hereunder to
purchase the Additional Shares to be sold on such Option Closing Date or (ii) purchase not less than the number of Additional Shares that such non-defaulting Underwriters would have been obligated to purchase in the absence of such default. Any
action taken under this paragraph shall not relieve any defaulting Underwriter from liability in respect of any default of such Underwriter under this Agreement. 
 If this Agreement shall be terminated by the Underwriters, or any of them, because of any failure or refusal on the part of the Selling Stockholders or the Company to comply with the terms or to fulfill any of the
conditions of this Agreement, or if for any reason the Selling Stockholders or the Company shall be unable to perform its obligations under this Agreement, the Company will reimburse the Underwriters or such Underwriters as have so terminated this
Agreement with respect to themselves, severally, for all out-of-pocket expenses (including the fees and disbursements of their counsel) reasonably incurred by such Underwriters in connection with this Agreement or the offering contemplated
hereunder. 
 11. Entire Agreement. (a) This Agreement, together with any contemporaneous written agreements and any prior
written agreements (to the extent not superseded by this Agreement) that relate to the offering of the Shares, represents the entire agreement between the Selling Stockholders, the Company and the Underwriters with respect to the preparation of any
preliminary prospectus, the Time of Sale Prospectus, the Prospectus, the conduct of the offering, and the purchase and sale of the Shares. 
 (b) Each Selling Stockholder and Company acknowledge that in connection with the offering of the Shares: (i) the Underwriters have acted at arms length, are not agents of, and owe no fiduciary duties to, such Selling Stockholder, the
Company or any other person, (ii) the Underwriters owe such Selling Stockholder and the Company only those duties and obligations set forth in this Agreement and prior written agreements (to the extent not superseded by this Agreement), if any,
and (iii) the Underwriters may 

  

 23 








 
have interests that differ from those of the Company or such Selling Stockholder. Each Selling Stockholder and the Company waive to the full extent permitted
by applicable law any claims each of them may have against the Underwriters arising from an alleged breach of fiduciary duty in connection with the offering of the Shares. 
 12. Counterparts. This Agreement may be signed in two or more counterparts, each of which shall be an original, with the same effect as if the
signatures thereto and hereto were upon the same instrument. 
 13. Applicable Law. This Agreement shall be governed by and construed
in accordance with the internal laws of the State of New York. 
 14. Headings. The headings of the sections of this Agreement have
been inserted for convenience of reference only and shall not be deemed a part of this Agreement. 
 15. Notices. All communications hereunder shall be in writing and effective only upon receipt and shall be delivered, mailed or sent to: (i) Morgan Stanley & Co. Incorporated, 1585 Broadway, New
York, New York 10036, Attention: Equity Syndicate Desk; (ii) the Selling Stockholders, to the addresses set forth in Schedule I; and (iii) the Company, 800 S. Douglas Road, 12th Floor, Coral Gables, Florida 33134, Attention: Albert de Cardenas Esq. 
  

 24 








 If the foregoing is in accordance with your understanding of our agreement, kindly sign and return to the
Company one of the counterparts hereof, whereupon it will become a binding agreement between the Company, the Selling Stockholders and the several Underwriters in accordance with its terms. 
  

			
	 Very truly yours,
  
 MASTEC, INC.

		
	By:	 	/s/ Alberto de Cardenas
	 Name:
 Title:
	 	 Alberto de Cardenas
 Executive Vice
President &
 General Counsel



  

 26 









			
	TRUST B UNDER THE AMENDED AND RESTATED LIVING TRUST OF LEO WANZEK
		
	By:	 	/s/ Jon Wanzek
	 Name:
 Title:
	 	 Jon Wanzek
 Trustee



  

 SIGNATURE PAGE TO UNDERWRITING AGREEMENT 









	
	 JANET L. WANZEK
  
 By: Jon L. Wanzek

	
	/s/ Jon Wanzek
	


  

 SIGNATURE PAGE TO UNDERWRITING AGREEMENT 









			
	THE WANZEK CONSTRUCTION 2008 IRREVOCABLE TRUST
		
	By:	 	/s/ Jon Wanzek
	 Name:
 Title:
	 	 Jon Wanzek
 Administrative
Trustee



  

 SIGNATURE PAGE TO UNDERWRITING AGREEMENT 









	
	JON L. WANZEK
	
	/s/ Jon Wanzek
	


  

 SIGNATURE PAGE TO UNDERWRITING AGREEMENT 









			
	THE JON L. WANZEK 2008 TWO-YEAR IRREVOCABLE ANNUITY TRUST
		
	By:	 	/s/ Jon Wanzek
	 Name:
 Title:
	 	 Jon Wanzek
 Trustee



  

 SIGNATURE PAGE TO UNDERWRITING AGREEMENT 








 The foregoing Agreement is hereby confirmed and 
 accepted as of the date first above written 
  

			
	MORGAN STANLEY & CO. INCORPORATED
		
	By:	 	/s/ Kent Hitchcock
	 Name:
 Title:
	 	 Kent Hitchcock
 Managing Director


  

 SIGNATURE PAGE TO UNDERWRITING AGREEMENT 








 SCHEDULE I 
  

							
	 Underwriter
	  	Number of
Firm Shares
	 Morgan Stanley & Co. Incorporated
	  	4,100,000
	 FBR Capital Markets & Co.
	  	400,000
	 Total
	  	4,500,000

  

							
	 Selling Stockholder
	  	Number of
Firm Shares	  	Number of
Additional
Shares
	 Trust B under the Amended and Restated Living Trust of Leo Wanzek dated February 2, 2000, a North Dakota trust
	  	1,941,940	  	291,291
			
	 Address:
 421 Harwood Drive S.
 Fargo, North Dakota 58104
 Janet L. Wanzek, a North Dakota resident
	  	126,032	  	18,905
			
	 Address:
 16550 37th Street
SE
 Fargo, North Dakota 58103
 The Wanzek Construction 2008 Irrevocable Trust, a North Dakota trust
	  	1,105,768	  	165,865
			
	 Address:
 421 Harwood Drive S.
 Fargo, North Dakota 58104
 Jon L. Wanzek, a North Dakota resident
	  	1,086,642	  	162,996
			
	 Address:
 421 Harwood Drive S.
 Fargo, North Dakota 58104
 The Jon L. Wanzek 2008 Two-Year Irrevocable
 Annuity Trust, a North Dakota trust
	  	239,618	  	35,943
			
	 Address:
 421 Harwood Drive S.
 Fargo, North Dakota 58104
	  		  	
	 Total
	  	4,500,000	  	675,000










 SCHEDULE II 
 Time of Sale Prospectus 
  

	 	1.	Preliminary Prospectus dated June 1, 2009 

  

	 	2.	Free Writing Prospectus dated June 1, 2009 








 SCHEDULE III 
 Significant Subsidiaries 
 MasTec North America, Inc. 
 DirectStar TV, LLC 
 Power Partners MasTec, LLC 
 Wanzek Construction, Inc.